BW-501C67
BW-501C67 is a peripherally selective serotonin 5-HT2A and 5-HT2C receptor antagonist which is used in scientific research. It shows selectivity for the serotonin 5-HT2 receptors over the α1-adrenergic receptor.
The drug antagonizes peripheral but not central effects of serotonin receptor agonists like serotonin. As examples, it has been found to antagonize the sympathomimetic effects of serotonin in animals, including vasoconstriction and pressor effects, but does not block centrally mediated effects like increased corticosterone secretion or myoclonus.
BW-501C67 and analogues were patented for use in combination with serotonin 5-HT2A receptor agonists like serotonergic psychedelics in 2023.